• DNDi logo
  • COVID-19
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Hepatitis C
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi logo
  • DNDi logo
  • COVID-19
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Hepatitis C
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Neglected tropical diseases & neglected patients
hepatitis-c icon

Hepatitis C

Meeting the needs of millions still waiting for affordable treatment

Home > Neglected tropical diseases & neglected patients
hepatitis-c icon

Hepatitis C

Meeting the needs of millions still waiting for affordable treatment

  • Overview
  • Facts
  • Projects & achievements

We are in the final stages of developing a simple-to-use, affordable cure and testing new strategies to link patients to lifesaving treatment and care. We are also working to foster the political will needed for wide-scale roll-out of test-and-treat strategies.

Hepatitis C is a blood-borne virus that can lead to chronic liver disease, cirrhosis, cancer, and, if not treated, death. Symptoms can take decades to develop and most people living with the disease do not know they are infected. As a result, hepatitis C is a silent epidemic.

Recent years have seen a revolution in medical innovation for hepatitis C, which can now be cured with just 8 to 24 weeks of safe, simple treatment. However, barely 7% of people living with the disease worldwide have benefited, largely because new drugs are priced out of reach for individuals and governments in countries hit hardest by the disease. In many countries, high prices are a major barrier for ‘test-and-treat’ strategies that have the potential to eliminate hepatitis C altogether.

 
Icon people in front of globe
0 million
people have hepatitis C
Icon interrogation point
0 %
are unaware they are infected
Icon treatment bottles
0 %
have had access to treatment
Icon people
0
people die every day
SEE DISEASE FACTS
DOWNLOAD FACTSHEET

‘Hepatitis C is a “silent epidemic” because people are unaware of their infection and go untreated for years.’

Sasikala Siva, DNDi Clinical Project Manager in Kuala Lumpur, Malaysia

What we are doing for people living with hepatitis C

Our goal is to deliver a treatment that is equal to the best hepatitis C drugs, at a fraction of the cost. To improve access to diagnosis and treatment of this silent epidemic, we are also supporting innovative programmes in several countries.

Clinical trials

Ravidasvir + sofosbuvir

An affordable cure to leave no one behind. We are working to develop a new simple-to-use, affordable treatment for hepatitis C that can increase access and minimize financial burden on patients and health systems. Interim trial results in Malaysia showed 97% of people treated were cured.

Registration & access

Hepatitis C Screening in Malaysia – #MYMissingMillions

Leading by example in access and innovation. A pioneer in efforts to tackle hepatitis C, the Malaysian government is joining with DNDi partner Foundation for Innovative New Diagnostics (FIND) to pilot the use of simple rapid diagnostic tests to link more people to lifesaving treatment and care.

see all projects

Making medical history for neglected patients

We develop urgently needed treatments for neglected patients and ensure they’re affordable, available, and adapted to the communities who need them

Doctor diagnosing a man in a village with his hands on the man's neck

Sleeping sickness

Is transmitted by the bite of a tsetse fly and causes severe neurological disorders

We delivered a revolutionary new drug to replace toxic treatments, and have ongoing trials to eliminate this disease

Young boy sitting on a hospital bed being examined by a nurse

Chagas disease

Causes heart and vital organ damage, after people are bitten by blood-sucking bugs

We delivered the first-ever treatment for children; now we’re searching for new drug candidates and working to boost access to care

Girl with skin lesions on her nose

Cutaneous leishmaniasis

Leaves disfiguring, life-long scars that lead to severe social stigma

We’re working to develop safer, shorter treatments for this disabling disease

Young man standing in the street

Hepatitis C

Millions are left without treatment even though effective drugs exist

We’re working to deliver a treatment as simple, safe, and effective as the best drugs available today – at a fraction of the cost 

Father walking in rural village with a cane and holding his son's hand

Filaria: river blindness

Lead to unbearable itching, disfiguring skin lesions, and even blindness

We’re working to develop a safe, effective, and affordable drug for the prevention and treatment of this debilitating disease

Woman standing in front of her door house in a rural village in Sudan

Mycetoma

Often ends in amputation​, after people get infected from stepping on a thorn

We’re conducting the world’s first trial for an alternative to current treatments, which are toxic and ineffective

Mother holding her baby in her arms smiling

Paediatric HIV

Without treatment, half of children die before their second birthday

We’ve developed a strawberry-flavoured treatment to meet the needs of children long neglected by the global HIV response

Girl looking over a fence

Visceral leishmaniasis

Is one of the world’s biggest parasitic killers, spread by the bites of sandflies

We’re working to develop a new generation of treatments to replace drugs that are painful, ineffective, and cause side effects

Chagas disease

Cutaneous leishmaniasis

Filaria: river blindness

Hepatitis C

Mycetoma

Paediatric HIV

Sleeping sickness

Visceral leishmaniasis

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

DNDi logo
Facebook-f Twitter Instagram Linkedin-in Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By continuing to browse our website, you are agreeing to our use of cookies.CLOSECOOKIE POLICY